0001193125-21-311286.txt : 20211028 0001193125-21-311286.hdr.sgml : 20211028 20211028160709 ACCESSION NUMBER: 0001193125-21-311286 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20211028 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211028 DATE AS OF CHANGE: 20211028 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RESMED INC CENTRAL INDEX KEY: 0000943819 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 980152841 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-15317 FILM NUMBER: 211358267 BUSINESS ADDRESS: STREET 1: 9001 SPECTRUM CENTER BLVD. CITY: SAN DIEGO STATE: CA ZIP: 92123 BUSINESS PHONE: 8587462400 MAIL ADDRESS: STREET 1: 9001 SPECTRUM CENTER BLVD. CITY: SAN DIEGO STATE: CA ZIP: 92123 8-K 1 d801447d8k.htm 8-K 8-K
RESMED INC US false 0000943819 0000943819 2021-10-28 2021-10-28

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Under Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

October 28, 2021

 

 

ResMed Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   001-15317   98-0152841

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

9001 Spectrum Center Blvd.

San Diego, California 92123

(Address of Principal Executive Offices)

(858) 836-5000

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

        

Title of each class

   

Trading

Symbol(s)

   

Name of each exchange

on which registered

Common Stock, $0.004 par value    RMD    NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act  ☐

 

 

 

Item 2.02.

Results of Operations and Financial Condition.

On October 28, 2021 we issued the press release furnished as Exhibit 99.1. The press release describes the results of our operations for the quarter ended September 30, 2021.

The information furnished in this Current Report on Form 8-K under Item 2.02 and the attached exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 8.01.

Other Events.

On October 28, 2021 we announced that our board of directors declared a quarterly cash dividend of US $0.42 per share. The dividend will have a record date of November 11, 2021, payable on December 16, 2021. The dividend will be paid in U.S. currency to holders of ResMed’s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Instruments trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be November 10, 2021 for common stockholders and for CDI holders. ResMed has received a waiver from the ASX’s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from November 10, 2021 through November 11, 2021, inclusive.

 

Item 9.01.

Financial Statements and Exhibits.

 

  (d)    Exhibits

 

Exhibits:

   

Description of Document

99.1    Press Release dated October 28, 2021 regarding results of operations
104    Cover Page Interactive Data File (embedded within the Inline XBRL, document)

 

-2-

SIGNATURES

We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934.

 

Date: October 28, 2021     RESMED INC.
    (registrant)
    By:  

/s/ Brett Sandercock

    Name:   Brett Sandercock
    Its:   Chief Financial Officer

 

-3-

EX-99.1 2 d801447dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO  

 

For investors    For media
Amy Wakeham    Jayme Rubenstein
+1 858-836-5000    +1 858-836-6798
investorrelations@resmed.com    news@resmed.com

ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2022

 

  -

Year-over-year revenue grows 20%, operating profit up 21%, non-GAAP operating profit up 18%

Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com

SAN DIEGO, October 28, 2021 – ResMed Inc. (NYSE: RMD, ASX: RMD), a world-leading digital health company, today announced results for its quarter ended September 30, 2021.

First Quarter 2022 Highlights

All comparisons are to the prior year period

 

  •  

Revenue increased by 20% to $904.0 million; up 19% on a constant currency basis

 

  •  

Gross margin of 56.0%; non-GAAP gross margin contracted 270 bps to 57.2%

 

  •  

Income from operations increased 21%; non-GAAP operating profit up 18%

 

  •  

Diluted earnings per share of $1.39; non-GAAP diluted earnings per share of $1.51

“Our first-quarter results demonstrate strong performance across our business with double-digit growth in both top-line and bottom-line metrics, driven by ongoing high demand for our sleep and respiratory care products, and steady growth across our software-as-a-service business,” said Mick Farrell, ResMed CEO. “It is through the extraordinary efforts of our global ResMed team that we were able to deliver products and solutions to our customers amid unprecedented supply chain challenges that continue to restrict access to critical electronic components. As we navigate supply limitations and are forced to allocate products, we continue to ensure priority for highest-acuity and highest-need patients first, as well as working with physicians, providers, and community systems to maintain a sustainable flow of medical devices and digital health solutions to patients who need care.”

“Despite constantly evolving market dynamics, we continue to pivot to meet the needs of our stakeholders, driving sustainable long-term growth, and ensuring that we are investing strongly in medical device research and development, as well as digital health innovation that will unlock value for all of our customers. I’m incredibly proud of our global teams that are working with providers and physicians in the most unusual times across 140 countries, to get products directly into the hands of patients who need our solutions most.”

 

RMD First Quarter 2022 Earnings Press Release – October 28, 2021

    Page 2 of 10

 

Financial Results and Operating Metrics

Unaudited; $ in millions, except for per share amounts

 

     Three Months Ended  
     September 30,
2021		     September 30,
2020		     % Change     Constant
Currency (A)		  

Revenue

    $ 904.0     $ 751.9       20 %      19 % 

Gross margin (B)

      56.0 %      58.3 %      (4 )   

Non-GAAP gross margin (B)

      57.2 %      59.9 %      (5 )   

Selling, general, and administrative expenses

      176.7       159.0       11       10  

Research and development expenses

      60.0       54.5       10       9  

Income from operations

      261.9       216.9       21    

Non-GAAP income from operations (B)

      280.7       237.1       18    

Net income

      203.6       178.4       14    

Non-GAAP net income (B)

      222.0       185.4       20    

Diluted earnings per share

    $ 1.39     $ 1.22       14    

Non-GAAP diluted earnings per share (B)

    $ 1.51     $ 1.27       19    

 

(A)

In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency” basis, which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

(B)

See the reconciliation of non-GAAP financial measures in the table at the end of the press release.

Discussion of First Quarter Results

All comparisons are to the prior year period unless otherwise noted

 

  •  

Revenue grew by 19% on a constant currency basis, driven by increased demand for our sleep and respiratory care devices and increased demand following a recent product recall by one of our competitors, partially offset by decreased COVID-19 related demand for ventilators.

 

  •  

The current quarter did not include material incremental respiratory care revenue from COVID-19 related demand whereas the prior year quarter included incremental revenue of approximately $40.0 million. Excluding the impact of incremental respiratory care revenue associated with COVID-19 in the prior year quarter, revenue increased by 25 percent on a constant currency basis.

 

  •  

Revenue in the U.S., Canada, and Latin America, excluding Software as a Service, grew by 22 percent, primarily due to the factors discussed above and recovery of core sleep patient flow that was previously impacted by COVID-19. Excluding the prior year impact of incremental respiratory care revenue associated with COVID-19, revenue increased by 28 percent.

 

  •  

Revenue in Europe, Asia, and other markets grew by 21 percent on a constant currency basis, primarily due to the factors discussed above and strong sales across our mask product portfolio. Excluding the prior year impact of incremental respiratory care revenue associated with COVID-19, revenue increased by 29 percent on a constant currency basis.

 

  •  

Software as a Service revenue increased by 6 percent, due to continued growth in resupply service offerings and stabilizing patient flow in out-of-hospital care settings.

RMD First Quarter 2022 Earnings Press Release – October 28, 2021

    Page 3 of 10

 

  •  

Gross margin decreased by 230 basis points and non-GAAP gross margin decreased by 270 basis points, mainly due to higher manufacturing costs, incremental freight costs, and lower average selling prices.

 

  •  

Selling, general, and administrative expenses increased by 10 percent on a constant currency basis. SG&A expenses improved to 19.5 percent of revenue in the quarter, compared with 21.1 percent in the same period of the prior year. These changes in SG&A expenses were mainly due to increases in employee-related expenses.

 

  •  

Income from operations increased by 21 percent and non-GAAP income from operations increased by 18 percent.

 

  •  

Net income grew by 14 percent and diluted earnings per share grew by 14 percent. Non-GAAP net income grew by 20 percent and non-GAAP diluted earnings per share grew by 19 percent, predominantly attributable to strong sales.

 

  •  

Operating cash flow for the quarter was negative $65.7 million and was impacted by a payment to the Australian Tax Office of $284.8 million, which was the settlement amount of $381.7 million net of prior remittances. After adjusting for this payment, our operating cash flow for the quarter was $219.1 million, compared to net income in the current quarter of $203.6 million and non-GAAP net income of $222.0 million. During the quarter we paid $61.2 million in dividends.

Other Business and Operational Highlights

 

  •  

Introduced the AirSense 11 in the U.S., ResMed’s next-generation PAP (positive airway pressure) device designed to help millions of people worldwide with sleep apnea start and stay on therapy to treat and manage obstructive sleep apnea.

 

  •  

Announced the promotion of Bobby Ghoshal to President of ResMed’s SaaS business.

 

  •  

Presented new research at the European Respiratory Society (ERS) International Congress 2021 including the landmark ALASKA study, “CPAP Termination and All-Cause Mortality: a French Nationwide Database Analysis,” that concludes people with obstructive sleep apnea who continue PAP therapy are 39% more likely to survive than OSA patients who don’t.

 

  •  

During the quarter, concluded the settlement agreement with the Australian Taxation Office (“ATO”), which fully resolves the transfer pricing dispute for all prior years since 2009. ResMed previously recognized a tax reserve in fiscal year 2021 in anticipation of the settlement.

 

  •  

The net impact of the settlement was $238.7 million ($381.7 million gross less credits and deductions of $143.0 million). The settlement provides closure for historic Australian tax matters and greater clarity into the future.

 

  •  

As a result of the ATO settlement and due to movements in foreign currencies, recognized a $4.1 million reduction in tax credits during the quarter, which was recorded as an increase in income tax expense.

Dividend program

The ResMed board of directors today declared a quarterly cash dividend of $0.42 per share. The dividend will have a record date of November 11, 2021, payable on December 16, 2021. The dividend will be paid in U.S. currency to holders of ResMed’s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests (“CDIs”) trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be November 10, 2021, for common stockholders and for CDI holders. ResMed has received a waiver from the ASX’s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from November 10, 2021, through November 11, 2021, inclusive.

RMD First Quarter 2022 Earnings Press Release – October 28, 2021

    Page 4 of 10

 

Webcast details

ResMed will discuss its first quarter fiscal year 2022 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on ResMed’s Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon for the “Q1 2022 Earnings Webcast” to register and listen to the live webcast. A replay of the earnings webcast will be accessible on the website and available approximately two hours after the live webcast. In addition, a telephone replay of the conference call will be available approximately two hours after the webcast by dialing +1 877-660-6853 (U.S.) or +1 201-612-7415 (outside U.S.) and entering the passcode 13723324. The telephone replay will be available until November 11, 2021.

About ResMed

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.

Safe harbor statement

Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding ResMed’s projections of future revenue or earnings, expenses, new product development, new product launches, new markets for its products, the integration of acquisitions, litigation, and tax outlook – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed’s periodic reports on file with the U.S. Securities & Exchange Commission. ResMed does not undertake to update its forward-looking statements.

 

 

– More –

RMD First Quarter 2022 Earnings Press Release – October 28, 2021

    Page 5 of 10

 

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(Unaudited; $ in thousands, except for per share amounts)

 

     Three Months Ended  
     September 30,
2021		     September 30,
2020		  

Net revenue

    $ 904,015     $ 751,944  

Cost of sales

      386,667       301,304  

Amortization of acquired intangibles (1)

      11,059       11,979  

Restructuring - cost of sales (1)

      —         —    
  

 

 

    

 

 

  

Total cost of sales

    $ 397,726     $ 313,283  
  

 

 

    

 

 

  

Gross profit

    $ 506,289     $ 438,661  

Selling, general, and administrative

      176,719       158,989  

Research and development

      59,950       54,533  

Amortization of acquired intangibles (1)

      7,707       8,243  
  

 

 

    

 

 

  

Total operating expenses

    $ 244,376     $ 221,765  

Income from operations

      261,913       216,896  

Other income (expenses), net:

     

Interest income (expense), net

    $ (5,360 )    $ (6,725 ) 

Loss attributable to equity method investments

      (1,386 )      (2,288 ) 

Other, net

      3,621       7,971  
  

 

 

    

 

 

  

Total other income (expenses), net

      (3,125 )      (1,042 ) 
  

 

 

    

 

 

  

Income before income taxes

    $ 258,788     $ 215,854  

Income taxes

      55,175       37,482  
  

 

 

    

 

 

  

Net income

    $ 203,613     $ 178,372  
  

 

 

    

 

 

  

Basic earnings per share

    $ 1.40     $ 1.23  

Diluted earnings per share

    $ 1.39     $ 1.22  

Non-GAAP diluted earnings per share (1)

    $ 1.51     $ 1.27  

Basic shares outstanding

      145,680       144,900  

Diluted shares outstanding

      146,860       146,100  

 

(1)

See the reconciliation of non-GAAP financial measures in the table at the end of the press release.

 

– More –

RMD First Quarter 2022 Earnings Press Release – October 28, 2021

    Page 6 of 10

 

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(Unaudited; $ in thousands)

 

     September 30,
2021		     June 30,
2021		  

ASSETS

     

Current assets:

     

Cash and cash equivalents

    $ 276,149     $ 295,278  

Accounts receivable, net

      575,554       614,292  

Inventories

      506,644       457,033  

Prepayments and other current assets

      227,908       208,154  
  

 

 

    

 

 

  

Total current assets

    $ 1,586,255     $ 1,574,757  

Non-current assets:

     

Property, plant and equipment, net

    $ 467,344     $ 463,490  

Operating lease right-of-use assets

      134,375       128,575  

Goodwill and other intangibles, net

      2,297,437       2,320,483  

Deferred income taxes and other non-current assets

      243,756       240,820  
  

 

 

    

 

 

  

Total non-current assets

    $ 3,142,912     $ 3,153,368  
  

 

 

    

 

 

  

Total assets

    $ 4,729,167     $ 4,728,125  
  

 

 

    

 

 

  

LIABILITIES AND STOCKHOLDERS’ EQUITY:

     

Current liabilities:

     

Accounts payable

    $ 173,696     $ 138,008  

Accrued expenses

      274,106       320,599  

Operating lease liabilities, current

      22,919       23,585  

Deferred revenue

      112,528       109,611  

Income taxes payable

      28,909       307,963  

Short-term debt

      12,000       12,000  
  

 

 

    

 

 

  

Total current liabilities

    $ 624,158     $ 911,766  

Non-current liabilities:

     

Deferred revenue

    $ 93,255     $ 91,496  

Deferred income taxes

      11,294       11,319  

Operating lease liabilities, non-current

      121,518       114,779  

Other long-term liabilities

      5,981       6,802  

Long-term debt

      793,668       643,351  

Long-term income taxes payable

      53,244       62,933  
  

 

 

    

 

 

  

Total non-current liabilities

    $ 1,078,960     $ 930,680  
  

 

 

    

 

 

  

Total liabilities

    $ 1,703,118     $ 1,842,446  
  

 

 

    

 

 

  

STOCKHOLDERS’ EQUITY:

     

Common stock

    $ 583     $ 583  

Additional paid-in capital

      1,643,661       1,622,199  

Retained earnings

      3,222,064       3,079,640  

Treasury stock

      (1,623,256 )      (1,623,256 ) 

Accumulated other comprehensive income

      (217,003 )      (193,487 ) 
  

 

 

    

 

 

  

Total stockholders’ equity

    $ 3,026,049     $ 2,885,679  
  

 

 

    

 

 

  

Total liabilities and stockholders’ equity

    $ 4,729,167     $ 4,728,125  
  

 

 

    

 

 

  

 

– More –

RMD First Quarter 2022 Earnings Press Release – October 28, 2021

    Page 7 of 10

 

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(Unaudited; $ in thousands)

 

     Three Months Ended  
     September 30,
2021		     September 30,
2020		  

Cash flows from operating activities:

     

Net income

    $ 203,613     $ 178,372  

Adjustment to reconcile net income to cash provided by operating activities:

     

Depreciation and amortization

      39,102       39,466  

Amortization of right-of-use assets

      8,517       10,422  

Stock-based compensation costs

      17,303       16,071  

Loss attributable to equity method investments

      1,386       2,288  

(Gain) loss on equity investment

      (5,612 )      (8,476 ) 

Changes in operating assets and liabilities:

     

Accounts receivable, net

      33,704       16,110  

Inventories, net

      (55,976 )      (52,396 ) 

Prepaid expenses, net deferred income taxes, and other current assets

      (14,391 )      3,415  

Accounts payable, accrued expenses, income taxes payable, and other

      (293,303 )      (61,273 ) 
  

 

 

    

 

 

  

Net cash (used in) / provided by operating activities

    $ (65,657 )    $ 143,999  

Cash flows from investing activities:

     

Purchases of property, plant, and equipment

      (27,340 )      (13,501 ) 

Patent registration and acquisition costs

      (4,453 )      (5,237 ) 

Purchases of investments

      (6,600 )      (8,196 ) 

(Payments) / proceeds on maturity of foreign currency contracts

      (3,481 )      4,824  
  

 

 

    

 

 

  

Net cash used in investing activities

    $ (41,874 )    $ (22,110 ) 

Cash flows from financing activities:

     

Proceeds from issuance of common stock, net

      4,354       1,026  

Taxes paid related to net share settlement of equity awards

      (195 )      227  

Proceeds from borrowings, net of borrowing costs

      150,000       55,000  

Repayment of borrowings

      —         (175,000 ) 

Dividends paid

      (61,189 )      (56,511 ) 
  

 

 

    

 

 

  

Net cash (used in) / provided by financing activities

    $ 92,970     $ (175,258 ) 
  

 

 

    

 

 

  

Effect of exchange rate changes on cash

    $ (4,568 )    $ 11,627  
  

 

 

    

 

 

  

Net increase / (decrease) in cash and cash equivalents

      (19,129 )      (41,742 ) 

Cash and cash equivalents at beginning of period

      295,278       463,156  
  

 

 

    

 

 

  

Cash and cash equivalents at end of period

    $ 276,149     $ 421,414  
  

 

 

    

 

 

  

 

– More –

RMD First Quarter 2022 Earnings Press Release – October 28, 2021

    Page 8 of 10

 

RESMED INC. AND SUBSIDIARIES

Reconciliation of Non-GAAP Financial Measures

(Unaudited; $ in thousands, except for per share amounts)

The measures “non-GAAP gross profit” and “non-GAAP gross margin” exclude amortization expense from acquired intangibles related to cost of sales and are reconciled below:

 

     Three Months Ended  
     September 30,
2021		     September 30,
2020		  

Revenue

    $ 904,015   $ 751,944

GAAP cost of sales

    $ 397,726   $ 313,283

Less: Amortization of acquired intangibles (A)

      (11,059 )      (11,979 ) 
  

 

 

    

 

 

  

Non-GAAP cost of sales

    $ 386,667   $ 301,304

GAAP gross profit

    $ 506,289   $ 438,661

GAAP gross margin

      56.0 %      58.3 % 

Non-GAAP gross profit

    $ 517,348   $ 450,640

Non-GAAP gross margin

      57.2 %      59.9 % 

The measure “non-GAAP income from operations” is reconciled with GAAP income from operations below:

 

     Three Months Ended  
     September 30,
2021		      September 30,
2020		  

GAAP income from operations

    $ 261,913    $ 216,896

Amortization of acquired intangibles - cost of sales (A)

      11,059      11,979

Amortization of acquired intangibles - operating expenses (A)

      7,707      8,243
  

 

 

     

 

 

  

Non-GAAP income from operations

    $ 280,679    $ 237,118
  

 

 

     

 

 

  

RMD First Quarter 2022 Earnings Press Release – October 28, 2021

    Page 9 of 10

 

RESMED INC. AND SUBSIDIARIES

Reconciliation of Non-GAAP Financial Measures

(Unaudited; $ in thousands, except for per share amounts)

The measures “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:

 

     Three Months Ended  
     September 30,
2021		      September 30,
2020		  

GAAP net income

    $ 203,613    $ 178,372

Amortization of acquired intangibles - cost of sales, net of tax (A)

      8,435      9,169

Amortization of acquired intangibles - operating expenses, net of tax (A)

      5,878      6,309

Reserve for disputed tax position (A)

      4,111      —    

(Gain) loss on equity investments (A)

      —          (8,476 ) 
  

 

 

     

 

 

  

Non-GAAP net income (A)

    $ 222,037    $ 185,374
  

 

 

     

 

 

  

GAAP diluted shares outstanding

      146,860      146,100

GAAP diluted earnings per share

    $ 1.39    $ 1.22

Non-GAAP diluted earnings per share (A)

    $ 1.51    $ 1.27

 

(A)

ResMed adjusts for the impact of the amortization of acquired intangibles, reserve for disputed tax positions and the (gain) loss on equity investments from their evaluation of ongoing operations and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.

ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight when evaluating ResMed’s performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.

 

– More –

RMD First Quarter 2022 Earnings Press Release – October 28, 2021

    Page 10 of 10

 

RESMED INC. AND SUBSIDIARIES

Revenue by Product and Region

(Unaudited; $ in millions, except for per share amounts)

 

     Three Months Ended  
     September 30,
2021 (A)		      September 30,
2020 (A)		      % Change     Constant
Currency (B)		  

U.S., Canada, and Latin America

           

Devices

    $ 275.9      $ 197.4        40 %   

Masks and other

      215.1        205.8        5    
  

 

 

     

 

 

     

 

 

    

Total Sleep and Respiratory Care

    $ 491.0      $ 403.2        22    

Software as a Service

      97.5        92.1        6    
  

 

 

     

 

 

     

 

 

    

Total

    $ 588.6      $ 495.3        19    
  

 

 

     

 

 

     

 

 

    

Combined Europe, Asia, and other markets

           

Devices

    $ 218.2      $ 176.0        24 %      22 % 

Masks and other

      97.2        80.6        21       18  
  

 

 

     

 

 

     

 

 

    

 

 

  

Total Sleep and Respiratory Care

    $ 315.5      $ 256.6        23       21  

Global revenue

           

Devices

    $ 494.2      $ 373.4        32 %      31 % 

Masks and other

      312.3        286.4        9       8  
  

 

 

     

 

 

     

 

 

    

 

 

  

Total Sleep and Respiratory Care

    $ 806.5      $ 659.8        22       21  

Software as a Service

      97.5        92.1        6       6  
  

 

 

     

 

 

     

 

 

    

 

 

  

Total

    $ 904.0      $ 751.9        20       19  
  

 

 

     

 

 

     

 

 

    

 

 

  

 

(A)

Totals and subtotals may not add due to rounding.

(B)

In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency basis,” which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

 

– End –

EX-101.SCH 3 rmd-20211028.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 rmd-20211028_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Entity Address, Country Entity Address, Country Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 rmd-20211028_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g801447g1028082126414.jpg GRAPHIC begin 644 g801447g1028082126414.jpg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end XML 7 d801447d8k_htm.xml IDEA: XBRL DOCUMENT 0000943819 2021-10-28 2021-10-28 RESMED INC US false 0000943819 8-K 2021-10-28 DE 001-15317 98-0152841 9001 Spectrum Center Blvd. San Diego CA 92123 (858) 836-5000 false false false false Common Stock, $0.004 par value RMD NYSE false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Oct. 28, 2021
Cover [Abstract]  
Entity Registrant Name RESMED INC
Entity Address, Country US
Amendment Flag false
Entity Central Index Key 0000943819
Document Type 8-K
Document Period End Date Oct. 28, 2021
Entity Incorporation State Country Code DE
Entity File Number 001-15317
Entity Tax Identification Number 98-0152841
Entity Address, Address Line One 9001 Spectrum Center Blvd.
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92123
City Area Code (858)
Local Phone Number 836-5000
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.004 par value
Trading Symbol RMD
Security Exchange Name NYSE
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://investor.resmed.com//20211028/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d801447d8k.htm d801447dex991.htm rmd-20211028.xsd rmd-20211028_lab.xml rmd-20211028_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d801447d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d801447d8k.htm" ] }, "labelLink": { "local": [ "rmd-20211028_lab.xml" ] }, "presentationLink": { "local": [ "rmd-20211028_pre.xml" ] }, "schema": { "local": [ "rmd-20211028.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "rmd", "nsuri": "http://investor.resmed.com/20211028", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d801447d8k.htm", "contextRef": "duration_2021-10-28_to_2021-10-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://investor.resmed.com//20211028/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d801447d8k.htm", "contextRef": "duration_2021-10-28_to_2021-10-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://investor.resmed.com//20211028/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://investor.resmed.com//20211028/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://investor.resmed.com//20211028/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://investor.resmed.com//20211028/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://investor.resmed.com//20211028/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://investor.resmed.com//20211028/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://investor.resmed.com//20211028/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://investor.resmed.com//20211028/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://investor.resmed.com//20211028/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://investor.resmed.com//20211028/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://investor.resmed.com//20211028/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://investor.resmed.com//20211028/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://investor.resmed.com//20211028/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://investor.resmed.com//20211028/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://investor.resmed.com//20211028/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://investor.resmed.com//20211028/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://investor.resmed.com//20211028/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://investor.resmed.com//20211028/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://investor.resmed.com//20211028/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://investor.resmed.com//20211028/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://investor.resmed.com//20211028/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://investor.resmed.com//20211028/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://investor.resmed.com//20211028/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001193125-21-311286-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-311286-xbrl.zip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end